Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 9/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.49 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.43 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | OGG1 | O15527 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6239212 | 0.94 | GRIA2 (0.58) | GRIA2KCNH2ADAMTS4PIP4K2APIP4K2B | |
| SCHEMBL6239372 | 0.85 | GRIA2 (0.60) | GRIA2KCNH2KDM1AAAK1CYP3A4 | |
| SCHEMBL6246776 | 0.84 | GRIA2 (0.44) | GRIA2KCNH2ADAMTS4PIP4K2APIP4K2B | |
| SCHEMBL6243805 | 0.82 | GRIA4 (0.44) | GRIA2KCNH2ADAMTS4KDM1A | |
| SCHEMBL6245808 | 0.81 | CA12 (0.41) | GRIA2KCNH2KDM1A | |
| SCHEMBL6243992 | 0.79 | GRIA2 (0.58) | GRIA2KCNH2KDM1AAAK1CYP3A4 | |
| SCHEMBL6236864 | 0.79 | ADAMTS4 (0.46) | GRIA2KCNH2ADAMTS4 | |
| SCHEMBL6239215 | 0.78 | GRIA2 (0.43) | GRIA2KCNH2ADAMTS4PIP4K2APIP4K2B | |
| SCHEMBL6242243 | 0.77 | CXCR2 (0.37) | GRIA2ADAMTS4 | |
| SCHEMBL7250833 | 0.76 | GRIA2 (0.74) | GRIA2KCNH2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395550-B1 | CYCLOALKENYLSULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | CANTELL BUDDY EUGENE (US) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157817-A1 | Cycloalkenylsulfonamide derivatives | GRIN2B, GRIN2A, GRIN1 | GRIA2 7/4885KCNH2 552/4885ADAMTS4 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.